Different Methods to Minimize Blood Loss During Laparoscopic Myomectomy; A Randomized Controlled Clinical Trial

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06566352

Enrollment

Registered

2024-08-22

Start date

2024-05-01

Completion date

2025-05-01

Last updated

2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Different Methods to Minimize Blood Loss During Laparoscopic Myomectomy

Brief summary

Detailed description

Laparoscopic myomectomy with temporary bilateral uterine artery occlusion or intramyometrial injection of diluted epinephrine will be important to reduce intraoperative bleeding, time of operation, and hospitalization period after laparoscopic myomectomy. This will be the first study to investigate the efficacy of Laparoscopic myomectomy with temporary bilateral uterine artery occlusion or intramyometrial injection of diluted epinephrine in minimizing blood loss during Laparoscopic myomectomy at our university. Can Laparoscopic myomectomy with temporary bilateral uterine artery occlusion or intramyometrial injection of diluted epinephrine give better outcomes regarding intraoperative bleeding when compared to traditional laparoscopic myomectomy?

Interventions

PROCEDURELaparoscopic myomectomy with intramyometrial injection of diluted epinephrine

intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution

PROCEDUREtraditional laparoscopic myomectomy

traditional laparoscopic myomectomy

PROCEDURElaparoscopic myomectomy with temporary bilateral uterine artery occlusion

Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion

DRUGinjection of epinephrine 1mg diluted in 200mg of NaCl

injection of epinephrine 1mg diluted in 200mg of NaCl

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 39 Years

Healthy volunteers

Inclusion criteria

1. Women aged from 18 to 39 years. 2. Symptomatizing Women (heavy menstrual bleeding or subfertility). 3. FIGO stage (3-7) by ultrasound. 4. Only uterine corpus fibroid. 5. Up to three fibroids by ultrasound. 6. No previous hormonal treatment.

Exclusion criteria

1. Patients with bleeding tendency. 2. Patients who refuse to participate in the study or uncooperative patients. 3. Current pregnancy. 4. Any retroperitoneal surgery at pararectal space. 5. More than one cesarean delivery.

Design outcomes

Primary

Measure	Time frame	Description
blood loss	intra-operative	estimated blood loss

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026